 CambridgeIP is a leading provider of technology business intelligence and IP-based strategy services to the technology community, capital firms, and policy makers. Contact us today for more information on how we can provide fact-based input for your key technology and IP strategy decisions. Contact Ilian Iliev CEO & co-Founder Contact Quentin Tannock, Chairman & co-Founder Contact Mark Meyer N. American Buisness Development Manager
Contacts: UK +44-1223-370-098 US +1-281-377-4260 CambridgeIP is headquarted in Cambridge, UK with representation in Boston, Houston, London and Geneva. |
|
| Greetings!
We would like to take a moment and share some of our exciting news and updates with you. Below you can learn more about:
- A recent Harvard Business Review article citing CambridgeIP's joint research with Chatham House in the CleanTech space
- Emerging trends in the inhaler drug delivery space
- Important developments in stem cells patenting
- Our new team members, Dr Robert Brady and Mr Peter Harverson
-The latest CambridgeIP Publications and Events information.
...and much more.
|
Harvard Business Review Article Features CambridgeIP Research
Harvard Business Review featured CambridgeIP research on cleantech in its January/February edition ('Can Technology Really Save Us from Climate Change?' Harvard Business Review). HBR's authors believe the CambridgeIP patent landscaping framework can underpin a 'Moore's Law' for low-carbon energy technologies. A 'Moore's Law' can support government and business decision making around long-term low-carbon energy deployment.
"To cut global emissions in half over the next 40 years, as scientists recommend, clean technologies must be rolled out on a vast scale. In the past, they have taken 19 to 30 years to achieve wide use, say researchers at the UK think tank Chatham House and the patent-search firm CambridgeIP... To be sure, powerful new market forces are at work: Governments beyond Europe are set to impose limits on greenhouse gases, and companies in a range of sectors are searching hard for ways to curb emissions. But technology deployment always takes time...That is particularly true of energy-related inventions, which tend to get into big trouble on their way out of the incubator and into the marketplace" (Harvard Business Review, January/February 2010:p. 21)
"The ability for IP Landscapes to track and analyze the clean-tech direction could 'pave the way for more-focused innovation, more-efficient use of capital, and more-realistic regulations".
|
Powder Inhaler (Patent #US7252087) |
Inhaler Drug Delivery
Innovation: A New Era for the Pharmaceutical Propellants?CambridgeIP's Arthur Lallement presented at the Drug Delivery for Lungs conference at Edinburgh on
December 9, 2009. Over four hundred senior scientists from the inhaler
and respiratory disease industry attended the conference and shared some
of the latest research in the inhaler space. For the last 20
years, the pharmaceutical industry has been developing propelled
formulations based on HydroFluoroAlcanes (HFA) in order to comply with
the Montreal Protocol banning the use of the ChloroFluoroAlcanes
depleting the ozone layer. Many of the inhaler industry's key players
were impacted significantly by the CFC ban, and in particular those in
the Propelled Metered Dose Inhaler (pMDI) space. Industry players'
strategy to adapt to the Montreal Protocol has broadly followed two
directions: pMDI space innovation and moving out of PMDIs. Now
almost 20 years later, many of the original propellant HFA patents are
expiring. This will result in many opportunities as well as threats for
key industry players. The patent expiration's will allow the
pharmaceutical industry to develop new pMDI formulations and to market
generic pMDI formulations...
...To continue reading about the 'New Era for the
Pharmaceutical Propellants' see our blog article here,
including a presentation on HFA pMDI Patent Landscape. Additionally,
CambridgeIP is holding a free Webinar on the topic of ' Inhaler Devices: Evolution, Regulatory Impact
and Emerging Innovations - Evidence and Techniques from patent-based
analysis' on Tuesday 27 April 2010; 15.00 - 16.00 UK time.
If you would like to learn more about CambridgeIP's drug delivery
device offering, please contact ilian.iliev@cambridgeip.com
|
'Who Owns Our Low-carbon
Future?' CambridgeIP and
Chatham House Report on Clean-Tech
Research conducted by CambridgeIP jointly with Chatham House (the Royal Institute of International
Affairs) has uncovered interesting trends that can inform investment and
growth strategies for companies in the low-carbon energy space. CambridgeIP
undertook an extensive analysis of patent ownership and the market
adoption rates of six low-carbon energy technologies: wind, solar
photovoltaic (PV), concentrated solar power, biomass-to electricity,
clean coal and carbon capture. We also looked at how company strategies
relate to different industry IP practices (such as cross-licensing
agreements or technology standards). Research and analysis
revealed that the pace of deployment in the six clean-tech sectors is
picking up. And this increasing deployment potentially suggests that
the time to market could be predictable for some clean technologies by
comparing patenting activity and technology roll-out. In addition,
growing complexity of the patent landscape in Wind and PV may be
contributing to increased IP litigation in these spaces. For
access to the full report from CambridgeIP and Chatham House click here.
|
|
Quentin Tannock presents a Chevening Lecture at Cambridge University on 'The Economics of Climate Change'
Following the Stern Review on 'the Economics of Climate Change', the Foreign and Commonwealth Office established a Chevening Fellowship course focusing on this topic. Each year the Course brings together a group of Fellows who have responsibility for advising their governments around the world on climate change. Quentin Tannock (Chairman and Founder) of CambridgeIP was invited by the University of Cambridge Programme for Sustainable Leadership, who are currently hosting the lectures, to present on research CambridgeIP has published. Quentin presented on the topic of 'The Economics of Climate Change: IP Ownership, Taking the Lead', covering ethical and policy issues, the facts on the ground in terms of IP ownership, the impact of international conventions and national policies on IP activity and the range of options for technology transfer in Low Carbon Technology spaces. Quentin concluded that much applicable Low Carbon Technology already exists, and the drivers and mechanisms for technology owners to undertake technology deployment can be identified. Policy-makers need to develop 'smart' technology and IP policies that consider the diversity of technologies, markets and players. Significant challenges remain with respect to valuation of, payment for and deployment of existing applicable technologies. However, much can be done to improve the transparency and efficiency of the current IP system, without radical overhaul. Importantly, patents published around the world represent a global technology library containing a wealth of freely available information. Improving access to this wealth of science and technology data should be a priority for policy-makers. To view the summary lecture presentation and entire blog piece on 'The Economics of Climate Change: IP Ownership, Taking the Lead' click here. |
|
'Patents and Potency'
Julian Hitchcock guest authors a piece on patenting in the complex world
of stem cells
[An excerpt from the article]
The grant of a
patent for induced pluripotent stem cells (iPSCs) in the United Kingdom
in January and the notice issued by the US Patent and Trademark Office
in February allowing claims under a US patent application entitled
"Methods for Reprogramming Somatic Cells" signal a significant new
feature of the stem cell patent landscape. But don't imagine that stem
cell patents are about to become straightforward.-
Paradigm Shift
The law
can sometimes be illuminated by a ludicrous interpretation. Such is the
case as regards the prohibition on patenting "processes for modifying
the germ line genetic identity of human beings" (Article 6b / Rule 28b):
the fact that a blot of induced totipotent cells never goes on to take
out a mortgage and raise a family being as irrelevant as the purpose
that happens to be stated in the relevant patent application. The
exception is questionable on many grounds. Ethically, it stands opposed
to the natural wish of parents to ensure that their children are
unharmed by genes which they would otherwise inherit. Technically, it
takes no account of the role of epigenetics: for example, it would
prevent the patentability of factors which might be applied in utero to
counter diseases arising from genomic imprinting. Indeed, epigenetics,-
the control of genetic expression by factors outside the genome, is
ultimately what iPSC technology is all about. One can put it more
strongly still, by saying that it is putting the cart before the horse
to talk of cells before talking of those factors which determine their
fate: cells are all phenotype, while th
eir fate is determined by genomic
control.
- The
author, Julian Hitchcock, is a Senior Associate of Field
Fisher Waterhouse LLP and Executive Director of the East of England Stem Cell Network.
To read
the full article click here. To
learn more about CambridgeIP's work in stem cells contact quentin.tannock@cambridgeip.com |
CambridgeIP Upcoming Events
This Week:
CambridgeIP will run an online webinar on the 27th of April for a small group on the topic of Inhaler
Devices: Evolution, Regulatory Impact and Emerging Innovations - Evidence and
Techniques from patent-based analysis
Synopsis: Ilian Iliev (CEO) and
Arthur Lallement (Senior Associate) will
present CambridgeIP research on the evolution of inhaler innovation in
the DPI
and pMDI spaces. The speakers will discuss two case study examples of
how
innovation is impacted by regulatory changes in the DPI and pMDI spaces -
around HFA propellants and dose counters. The session will cover
emerging trends and developments, and examples of emerging technologies
in the
inhaler space will be provided.
27 April 2010, Start time 15.00 UK Time - End
time 16.00 UK Time. Attendance is free
To register and obtain joining instructions
contact Sarah Helm (Sarah.Helm@cambridgeip.com)
Mark your calenders:
6th May 2010: Quentin
Tannock (Chairman) will present at BIO
2010 in Chicago, USA
on the topic of "Fact-based strategy development: Accelerating your
out-licensing". Case study examples will be provided from the Inhalers
sector and Quentin will discuss Inhaler Related Evolution, Regulatory
Impact and Emerging Innovations.
11th May 2010: CambridgeIP is running a free online webinar lead by Mark Meyer (N. American Business Development Manager) for a small group on the topic of US Practices.
13th-14th May 2010: Ilian Iliev (CEO) was invited to speak at the 'Trade, Financing and Climate Change: Towards a positive agenda for developing countries' conference hosted by Chatham House and DFID on the topic of: Intellectual Property and Low Carbon Technological Diffusion.
18th May 2010: CambridgeIP is running a free online webinar lead by Quentin Tannock (Chairman) for a small group on the topic of Developing a Fact Based IP Strategy.
1st June 2010: CambridgeIP is running a free online webinar lead by Quentin Tannock (Chairman) for a small group on the topic of Nanotechnology.
15th June 2010: CambridgeIP is running a free online webinar lead by Helena van der Merwe (Senior Associate) on the topic of Telecoms.
Details of the upcoming webinars are still being organized, but if any of the topics are of interest please contact Sarah.Helm@cambridgeip.comfor further information closer to the date.
|
CambridgeIP
Team News We are pleased to announce two new additions to the CambridgeIP
team. Dr Robert Brady has joined our Board of Directors, and Mr Peter
Harverson has joined our Advisory Board. See profiles of both of our latest
team members below.
Dr Robert Brady has
joined the CambridgeIP
Board as a non-Executive Director. Dr Brady acts as an active mentor and
advisor for several growth companies, specializing in information
technology
and services. He is current treasurer of Cambridge Angels investment
group. Previously, Dr Brady was a Fellow at Trinity College, Cambridge
where he specialized in the field of physics. His published research
includes
two articles in Nature on computer optimization strategies and
electrolysis of
copper sulfate. In 1985 he began his commercial career with the
founding
of Brady plc. Brady plc has grown into a leading supplier of
transaction
and risk management software solutions to companies and banks operating
in the
metals and minerals, energy and 'soft' commodity sectors.
Mr Peter Harverson has joined the
CambridgeIP
Advisory Board. Mr Harverson has held a number of senior executive
roles at NASDAQ/NYSE companies such as Texas Instruments, Intel Corp,
Daisy
Systems, Valid Logic, Cadence Design Systems and Sun Microsystems. Notably, while at Sun Microsystems he
headed the entire development of the companies European Corporate
Accounts
programme. More recently Peter
Haverson has used his technical background and extensive experience of on technology market to assist in the operational management of
numerous growth companies. Mr Peter Haverson currently acts as
non-executive
director to Ubisense Ltd, Aspex Semiconductor Holdings Ltd, CRFS Ltd and
as an
adviser to Pulsic Ltd. Other
News
Ilian Iliev (CEO & Founder) was
recently appointed as an Associate Fellow at Chatham House.
|
Read More: CambridgeIP Publications, Presentations and Media
Links to the most recent CambridgeIP Publications and Media. For a complete archive see here.
Publications & Media
'Can Technology Really Save Us from Climate Change?' Harvard Business Review [January/February 2010
edition].
'Challenges and Opportunities in the licensing of renewable technologies' Journal of Commercial Biotechnology[Volume 16,
Issue 1; pp. 47-52]. Article co-authored by Meredith Lloyd-Evans,
Mike Gilbert, and Ilian Iliev.
'The Importance of IP' Renewable Energy Focus Finance Supplement
(pp. 18-20). Ilian Iliev and Mark Meyer.
'Heavy industry key to carbon reduction',interview with Ilian
Iliev, The Engineer, September 2009.
Presentations
Quentin Tannock of CambridgeIP presented a Chevening Fellowship Lecture
at the University of Cambridge on 'The Economics of Climate Change: Taking a lead - IP Ownership'.
Ilian Iliev of CambridgeIP presented at the CUTEC 'Leveraging IP in a Globalised World'workshop in Cambridge addressing the development
of intellectual property in a globalised economy.
CambridgeIP presented with Dr. Phillippe Rogueda at the Drug Delivery to the Lungs (DDL) conferenceon the
topic of 'The HFA pMDI Patent Landscape: Minefield or Goldmine?'.
Mark Meyer of Cambridge IP
presented at the American Institute of Chemical Engineers (AICHE)
Spring Meeting in San Antonio. The topic presented was regarding
'IP Strategy Options for Emerging Technologies in the Low-Carbon
Energy Space'.
Social Media
CambridgeIP is now on Twitter! Follow us to keep up with the latest news and updates.
To stay connected with CambridgeIP's professional network, join our LinkedIn group.
|
About CambridgeIP
Please feel free to get in touch with our principals: Quentin Tannock: quentin.tannock@cambridgeip.com Ilian Iliev: ilian.iliev@cambridgeip.com Mark Meyer: mark.meyer@cambridgeip.comTel UK +44-1223-370-098 Tel US +1-281-377-4260 About Us
CambridgeIP is a provider of technology, business intelligence and IP strategy services to the technology community and policy makers.
The company has a proprietary platform enabling efficient handling, real time analysis and online display of large patent (and other structured data) datasets, unique analytics, and highly granular focus at the level of individual technology, inventor or organisation. We provide fact-based IP strategy, R&D and investment due diligence services to the technology community at large.
We have representatives in Cambridge and London (UK), Houston and Boston (USA) and Geneva (Switzerland)
Mailing Address: Cambridge Intellectual Property Ltd, Sheraton House, Castle Park, Cambridge, CB3 0AX, United Kingdom Visit www.cambridgeip.com for more details.
Disclaimer
This newsletter includes analysis, together with opinions or financial observations expressed by CambridgeIP. They do not constitute legal advice. The reader should not rely on them to make (or to refrain from making) any decision. Any decision is the reader's sole responsibility.
|
|
|
|
|